Arvinas is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC⢠protein degraders, that are designed to harness the bodyâs own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Source
No articles found.
Harvard Bioscience is a global developer, manufacturer and marketer of a broad ran...
Harvard Bioscience is a global developer, manuf...
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to ...
ImmunoGen is developing the next generation of ...
Inogenâs mission to improve the quality of life of supplemental oxygen users beg...
Inogenâs mission to improve the quality of li...
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, d...
Rigel Pharmaceuticals, Inc. is a biotechnology ...
Join the National Investor Network and get the latest information with your interests in mind.